Literature DB >> 19587705

Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma.

M Roussou, A Tasidou, M A Dimopoulos, E Kastritis, M Migkou, D Christoulas, M Gavriatopoulou, F Zagouri, C Matsouka, D Anagnostou, E Terpos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19587705     DOI： 10.1038/leu.2009.130

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  26 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

Review 2.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

3.  Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.

Authors:  Ahmed T Kurdi; Siobhan V Glavey; Natalie A Bezman; Amy Jhatakia; Jennifer L Guerriero; Salomon Manier; Michele Moschetta; Yuji Mishima; Aldo Roccaro; Alexandre Detappe; Chia-Jen Liu; Antonio Sacco; Daisy Huynh; Yu-Tzu Tai; Michael D Robbins; Jamil Azzi; Irene M Ghobrial
Journal:  Mol Cancer Ther       Date:  2018-04-13       Impact factor: 6.261

Review 4.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 5.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

Review 6.  unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?

Authors:  Matthew T Drake
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

7.  CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.

Authors:  Daniel J Dairaghi; Babatunde O Oyajobi; Anjana Gupta; Brandon McCluskey; Shichang Miao; Jay P Powers; Lisa C Seitz; Yu Wang; Yibin Zeng; Penglie Zhang; Thomas J Schall; Juan C Jaen
Journal:  Blood       Date:  2012-05-22       Impact factor: 22.113

8.  Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Authors:  Adel Ersek; Ke Xu; Aristotelis Antonopoulos; Terry D Butters; Ana Espirito Santo; Youridies Vattakuzhi; Lynn M Williams; Katerina Goudevenou; Lynett Danks; Andrew Freidin; Emmanouil Spanoudakis; Simon Parry; Maria Papaioannou; Evdoxia Hatjiharissi; Aristeidis Chaidos; Dominic S Alonzi; Gabriele Twigg; Ming Hu; Raymond A Dwek; Stuart M Haslam; Irene Roberts; Anne Dell; Amin Rahemtulla; Nicole J Horwood; Anastasios Karadimitris
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

9.  Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma.

Authors:  Baptiste Lamarthée; Frédéric de Vassoigne; Florent Malard; Nicolas Stocker; Inès Boussen; Clémence Médiavilla; Ruoping Tang; Fanny Fava; Laurent Garderet; Zora Marjanovic; Eolia Brissot; Mohamad Mohty; Béatrice Gaugler
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

10.  Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.

Authors:  A Gilchrist; T D Gauntner; A Fazzini; K M Alley; D S Pyen; J Ahn; S J Ha; A Willett; S E Sansom; J L Yarfi; K A Bachovchin; M R Mazzoni; J R Merritt
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.